Aurixim is under clinical development by BioIntegrator and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Aurixim’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aurixim is under development for the treatment of B-cell Non-Hodgkin lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, small lymphocytic lymphoma, lymphoma of lien marginal zone cells. The drug candidate is an infusion, which is administered through intravenous route. It is a rituximab conjugate and acts by targeting CD20.
BioIntegrator, a subsidiary of ChemRar High-Tech Center, is focused on the development and production of drugs based on recombinant proteins and small molecules for the treatment of autoimmune and oncological diseases. BioIntegrator is headquartered in Moscow, Russia.
For a complete picture of Aurixim’s drug-specific PTSR and LoA scores, buy the report here.